« Return to News | Drug Sponsors

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

The incidence of non-small-cell lung cancer in Russia is the highest among the BRIC (Brazil, Russia, India, China) markets and is comparable to that of the United Kingdom and the United States. Increasing risk of non-small-cell lung cancer due to increasing smoking prevalence in men, in conjunction with an aging population, will drive an increase in incident non-small-cell lung cancer cases in Russia.

As the incident non-small-cell lung cancer population grows in Russia, sales of most drug classes are expected to grow through 2015,” said Decision Resources analyst Natalia Reoutova. “The most dramatic growth will likely be seen in the kinase inhibitors drug class where three emerging agents—Boehringer Ingelheim’s Tovok, Pfizer’s dacomitinib and ArQule/Daiichi Sankyo/Kyowa Hakko Kirin’s tivantinib—should make their debut in or before 2015.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.